Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline reports positive data from Parkinson’s drug trial

GlaxoSmithKline reports positive data from Parkinson’s drug trial

16th March 2011

GlaxoSmithKline has published positive clinical trial data from a new phase III study of IPX066, a new treatment for Parkinson's disease.

The company's partner Impax Pharmaceuticals has conducted a trial to gauge the efficacy of the drug among advanced Parkinson's patients with motor fluctuations, compared to a leading alternative.

It was found that IPX066 was able to meet its primary endpoint of reducing the amount of "off time" experienced by patients, in which their medication has worn off and symptoms have returned.

This study is the second of three planned phase III studies for the compound, with the first demonstrating its effectiveness when compared to placebo.

Should the development efforts prove successful, GlaxoSmithKline will gain rights to commercialise the product in all global territories other than the US and Taiwan, where it will be sold by Impax.

Earlier this month, GlaxoSmithKline's kidney cancer drug Votrient was approved for use among Scottish NHS patients by the Scottish Medicines Consortium.ADNFCR-8000103-ID-800464314-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.